SCHEMBL26255193

SCHEMBL26255193

C1=C(CCNc2ncnc3c2ncn3C2CC2)CCCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ YTHDC1 Q96MU7 1/20 0.51
▸ MAPT P10636 6/20 0.49
▸ ALDH1A1 P00352 4/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ KDM4E B2RXH2 3/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ TP53 P04637 4/20 0.48
▸ HTT P42858 3/20 0.48
▸ LMNA P02545 3/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ GALR3 O60755 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ ADORA2A P29274 5/20 0.43
▸ PI4KA P42356 3/20 0.43
▸ PI4K2B Q8TCG2 3/20 0.43
▸ PI4K2A Q9BTU6 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24197042 0.96 YTHDC1 (0.53) YTHDC1MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL24197039 0.80 ADORA2A (0.60) MAPTALDH1A1SMN1; SMN2KDM4ERAB9A
SCHEMBL26255159 0.77 MAPT (0.64) MAPTALDH1A1SMN1; SMN2KDM4ERAB9A
SCHEMBL26255178 0.77 YTHDC1 (0.58) YTHDC1SMN1; SMN2RAB9ANPC1ADORA2A
SCHEMBL24197041 0.77 YTHDC1 (0.52) YTHDC1SMN1; SMN2RAB9ANPC1ADORA2A
SCHEMBL26255175 0.76 YTHDC1 (0.59) YTHDC1SMN1; SMN2RAB9ANPC1ADORA2A
SCHEMBL24197135 0.74 YTHDC1 (0.64) YTHDC1ADORA2API4KAPI4K2BPI4K2A
SCHEMBL26255182 0.74 YTHDC1 (0.60) YTHDC1SMN1; SMN2RAB9ANPC1ADORA2A
Hydrochloric Acid SCHEMBL27438627 0.74 TSHR (0.50) YTHDC1MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL26255179 0.73 YTHDC1 (0.63) YTHDC1SMN1; SMN2RAB9AKMT2AADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279006-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLOTHO THERAPEUTICS, INC. 2023-09-07 — — US disclosed
US-20230279006-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLOTHO THERAPEUTICS, INC. 2023-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279006-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLKB1, KLK2, KLK1 YTHDC1 2838/4885MAPT 4363/4885ALDH1A1 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback